May 11, 2023
Tesis Biosciences Announces New Test That Can Identify Those in Most Danger from Covid-19
PHOENIX, May 11, 2023 /PRNewswire/ — Tesis Biosciences, the leader in targeted genetic sequencing, has developed a new test that identifies the genetic mutations that puts people in the greatest danger from the Covid-19 virus.
Widespread use of the tests could save hundreds of thousands of lives and lessen the severity of the illness in others by identifying the need for early and aggressive treatment and encouraging those who are susceptible to take precautions against contracting the disease, according to Divyen H. Patel, Ph.D., chief research officer at Tesis Biosciences.
CONTACT US
April 20, 2023
Tesis Biosciences Announces a Novel Pharmacogenomics Test Enabling Precise, Personalized Response to Wide Range of Pharmaceuticals
PHOENIX, April 20, 2023 /PRNewswire/ — Tesis Biosciences, the leader in targeted genetic sequencing, has announced a new predictive genomic assay that will allow physicians to more accurately identify appropriate drug therapies and dosages for patients suffering from hundreds of diseases and conditions. The new pharmacogenomics test will make drug therapy more precise, reduce the number of adverse drug reactions, and save millions in treatment costs by assessing how patients will metabolize drugs based on their genetic makeup, which can determine how effective the drug will be.
Dec 09, 2022
Tesis Biosciences Announces Proposed Study of Veterans and Civilians with Mild Traumatic Brain Injury
PHOENIX, Dec. 9, 2022 /PRNewswire/ — Tesis Biosciences, the leader in targeted genetic sequencing, has announced a proposed study designed to develop molecular biomarkers to precisely differentiate mild traumatic brain injury (mTBI) from post-traumatic stress disorder (PTSD). Enabling a precise diagnosis can improve treatments for individuals who are susceptible for mTBI and PTSD such as U.S. military members and athletes as well as civilians of all ages.
The new study will use a high-throughput genomics approach to analyze peripheral blood mononuclear cells (PBMC) from mTBI-affected and non-TBI-affected veterans and civilians. The study will seek to identify complex changes in micro-RNA (miRNA) levels that may function as a sensitive and specific biomarker panel for mTBI. Each group in this cohort will also be matched for PTSD.
May 24, 2022
Tesis Biosciences to Provide Genetic Testing Services for Florida ACO Pathways Health Partners
PHOENIX and LEESBURG, Fla., May 24, 2022 /PRNewswire/ — Tesis Biosciences, the leader in targeted genetic sequencing, has been selected by Pathways Health Partners (PHP), an accountable care organization (ACO) dedicated to solving the challenges facing healthcare today, to provide member practices with next-generation sequencing (NGS) testing and precision medicine services for the detection and prevention of chronic and hereditary conditions in patients.
Founded in 2018, PHP deploys integrated capabilities to support value-based care. The company’s care management services focus on where they can have the greatest impact on health outcomes, while its technology platform predicts which patients are most likely to experience serious, preventable medical episodes. PHP’s analytics capabilities measure real-time performance, cost, risk, and productivity against strategy and goals to prevent unnecessary spending and close care gaps to improve member quality scores.
March 16, 2022
Tesis Biosciences Partners with Frontier Management to Provide Exclusive Pharmacogenetic Testing for Residents of Frontier’s Senior Living Facilities
PHOENIX and PORTLAND, Ore., March 16, 2022 /PRNewswire/ — Tesis Biosciences, the leader in targeted genetic sequencing, and Frontier Management, one of the largest senior housing providers in the U.S., have announced an agreement under which Tesis will be the exclusive provider of pharmacogenetic testing for residents of the company’s communities.
Frontier operates more than 130 independent living, assisted living and memory care facilities across 21 states. As part of its package of services to residents, Frontier provides basic healthcare. Under this agreement, Tesis will conduct all pharmacogenetic testing for Frontier facility residents and serve as the testing arm of Frontier’s pharmaceutical management program for residents.
Feb 16, 2022
Tesis Biosciences Acquires Genome Explorations to Accelerate Clinical Research and Product Development for Chronic Disease Cures
PHOENIX and MEMPHIS, Tenn., Feb. 16, 2022 /PRNewswire/ — Tesis Biosciences, the leader in targeted genetic sequencing, has acquired Genome Explorations, a premier research institution providing global genomic profiling and molecular diagnostics services.
The acquisition, which aligns with Tesis Biosciences’ increased focus on clinical research and product development, will allow Tesis to expedite the completion of a therapeutic clinical initiative that could result in a proprietary product reaching the market in early 2022, pending authorization.
Genome Explorations serves academic centers, pharmaceutical and biotech industry, oncologists, and pathologists with innovative diagnostic, prognostic, predictive, and personalized testing. Its highly trained existing clinical and research staff, which focuses on global genomic profiling and molecular diagnostics services, will complement, and augment the internal Tesis research staff in accelerating development of proprietary products that will transform how chronic diseases are treated.
Nov 16, 2021
Tesis Labs Announces Name Change to Tesis Biosciences
PHOENIX, Nov. 16, 2021 /PRNewswire/ — Tesis Biosciences, a leader in targeted genetic sequencing, announced its new company name – Tesis Biosciences, to reflect the organization’s increasing focus on advancing clinical research and diagnostic initiatives through collaborative relationships with important healthcare stakeholders.
Tesis Biosciences uses a genetically integrated medical platform for targeted genetic sequencing and comprehensive genetic data collection to support multiple medical specialties. The company partners with medical device and drug manufacturers to help them improve the likelihood of success for their clinical trials and provide them with better diagnostic outcomes. Tesis also works with hospitals, health systems, value-based care organizations, research organizations and others to offer next-generation genetic sequencing to improve patient care and quality outcomes.
Oct 13, 2021
John Shufeldt, M.D., Joins Tesis Labs Board of Directors
PHOENIX, Oct. 13, 2021 /PRNewswire/ — Tesis Labs, a leader in targeted genetic sequencing, announced today the addition of John Shufeldt, M.D., to its company board of directors.
He currently leads Tribal EM a large medical staffing and management company devoted to caring for Indigenous People and continues to practice emergency medicine and health law. Working as a business leader and consultant, Dr. Shufeldt helps clients like hospital groups and healthcare companies with leadership coaching and business strategy. As an experienced and published author, he has written 10 books and 2 textbooks covering a variety of topics, including personal growth, entrepreneurism, stoicism, urgent care medicine and management, and leadership.
Oct 05, 2021
Tesis Labs Raises $20 Million in Growth Equity Capital to Expand Clinical Capacity
PHOENIX, Oct. 5, 2021 /PRNewswire/ — Tesis Labs, a leader in targeted genetic sequencing, announced $20 million of growth equity financing at a post-money valuation of $520 million. The round was led by Xcellerant 1 TLC, LLC, an investment group headed by John Shufeldt, M.D.,
This is the first external financing for Tesis Labs since it initiated operations in early 2020. Prior to this funding, the Company raised approximately $15 million.
Tesis Labs offers healthcare providers and physicians access to unique genetic testing and precision medicine, enabling them to create personalized care plans for treating chronic diseases – individually and across generations. The Tesis mission is to change medicine by providing physicians, hospitals, and researchers with treatment tools to help patients overcome major chronic conditions such as heart disease, lung disease, and cancer through advanced genetic testing.
September 16, 2021
Tesis Labs partners with Georgia’s Premier Health to offer preventive testing
Phoenix-based genetic sequencing company Tesis Labs is partnering with Atlanta-based Premier Health to offer genetic testing to patients in the state, Tesis said Sept. 15.
The testing is intended to provide an early warning for chronic or hereditary conditions. Tesis will initially perform testing for Premier Health out of its Lafayette, Colo., facility, eventually moving the testing services to Premier’s Georgia sites.
September 15, 2021
Tesis Labs to Provide Genetic Testing Services for Premier Health ACO with operations throughout Georgia
PHOENIX, Sept. 15, 2021 /PRNewswire/ — Tesis Labs, the leader in targeted genetic sequencing, announced it has been selected by Premier Health, an accountable care organization (ACO) serving communities in Georgia to provide clinicians and practices in the ACO with high-complexity molecular and next-generation sequencing (NGS) testing services for detecting chronic and hereditary conditions in patients.
With approximately 200 member providers practicing primary care, internal medicine and other specialties, Premier Health collectively treats tens of thousands of patients each year in central and western Kentucky and Georgia. While initial testing for Premier Health will be performed at the Tesis Labs facility in Lafayette, Colo., the company plans to eventually locate lab services at Premier sites in Georgia as part of a joint venture.
September 14, 2021
Jonathan Stein, Ph.D., HCLD(ABB), joins Tesis Labs as Chief Science Officer
PHOENIX, Sept. 14, 2021 /PRNewswire/ — Tesis Labs, a leader in targeted genetic sequencing, has named life sciences lab veteran Jonathan Stein, Ph.D., HCLD(ABB), as the company’s first chief science officer and medical director.
Tesis uses a genetically integrated medical platform for targeted genetic sequencing and comprehensive genetic data collection to support many medical specialties. The company collaborates with hospitals, health systems, value-based care organizations, medical device companies, research organizations and others to offer next-generation genetic sequencing designed to improve patient care and quality outcomes.
August 11, 2021
TESIS LABS, PERSONAL GENOME DIAGNOSTICS INK MARKET ACCESS PARTNERSHIP
NEW YORK – Tesis Labs and Personal Genome Diagnostics said Tuesday that they are collaborating to develop new genomic tests for cancer patients that combine somatic and germline variant results, with the goal of advancing market access and accelerating adoption of their products.
In an email, PGDx said that the companies intend to combine Tesis’ genomic data and reporting capabilities with somatic variant outputs from certain tissue tests to create a “comprehensive platform that provides patients with a streamlined experience … [combining] germline and somatic variants into a single clinical report.”
August 10, 2021
TESIS LABS AND PERSONAL GENOME DIAGNOSTICS ANNOUNCE COLLABORATION
TO ADVANCE CANCER PROFILING AND TREATMENT
BALTIMORE & HOUSTON, August 10, 2021–(BUSINESS WIRE)–Tesis Labs, a leader in targeted genetic sequencing, and Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a new collaboration to maximize the power of genetic sequencing and bioinformatics. Through this collaboration, the companies intend to combine resources and expertise to create new genomics solutions that could combat cancer and improve outcomes for patients, and advance market access initiatives to accelerate adoption in the market.
The National Institutes of Health estimates that by 2040, there will be 29.5 million new cancer cases and nearly 16.4 million deaths worldwide per year. This new strategic collaboration brings together highly specialized clinical laboratory and biotechnology teams, enabling their expertise, creativity, and passion for delivering the latest genetic and bioinformatic insights to advance cancer predisposition, profiling, and treatment.
Apr 07, 2021
TESIS LABS LAUNCHING NEW ARIZONA GENETIC TESTING FACILITY – OPENING NOVEMBER 2021
Tesis Labs, the leader in targeted genetic sequencing, announced its plans to expand to the Phoenix/Scottsdale area, offering targeted genetic sequencing services to healthcare providers in the western U.S. The new lab will be located in Scottsdale.
The Scottsdale lab will provide the additional capacity to handle the growth of the Company’s collaborative initiatives with large medical companies and research organizations looking to develop pharmaceuticals that impact the human genome, medical devices and large medical organizations focused on an improvement in the quality of care. The primary focus of the facility will be on high-complexity molecular and next-generation sequencing (NGS) testing to detect chronic and hereditary conditions such as cancer, heart disease, lung disease, diabetes, and Alzheimer’s. Also, the lab will offer Infectious Disease testing, including COVID-19, respiratory pathology, wound, and other molecular testing.
March 31, 2021
NATERA AND TESIS LABS ANNOUNCE STRATEGIC COLLABORATION ON PRENATAL GENETIC TESTING
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, and Tesis Labs, a US multi-region lab services provider with labs in Colorado, Texas and Arizona, announced a strategic partnership in the field of prenatal genetic testing.
The collaboration will allow Tesis to broaden its portfolio of genetic testing offerings and participate in the fast growing screening market for over 4 million pregnancies in the United States. Tesis’s state-of-the-art and highly scalable genetics laboratory in Lafayette, Colorado can serve many regions of the U.S. including Texas, Arizona, and Colorado.
